Skip navigation

Patient taking Novartis MS pill developed rare disease

ZURICH (Reuters) - A patient taking Novartis' multiple sclerosis pill Gilenya developed a rare and potentially fatal viral disease, the Swiss drugmaker said on Tuesday, an unexpected setback as it faces growing competition from new oral treatments.Full story

Novartis vaccine division hit by Bexsero setback

ZURICH (Reuters) - Swiss drugmaker Novartis suffered a fresh blow to the turnaround prospects of its loss-making vaccines division as a key committee advised against including its meningitis B vaccine on Britain's routine vaccination program. Full story

News Summary: Novartis Q2 profit dips, ups outlook

PROFIT DOWN: Swiss pharmaceutical company Novartis AG posting a 5 percent net income drop in the second quarter. Full story

Sponsored Links

Articles

Novartis lifts full-year outlook after competition delay

Novartis psoriasis drug superior to Enbrel in study

EU approves Novartis eye drug for new use

Novartis skin drug helps patients with chronic hives

Alliance Pharma buys rights to Novartis' obstetric drug Syntometrine

Novartis says study shows Gilenya benefits patients with MS

U.S. sues Novartis over kickbacks, second case this week

UK health cost body backs Novartis asthma drug in fresh U-turn

EU approves Novartis drug for gout

Novartis golden handshake angers shareholders, politicians

Related Photos

A Novartis logo is pictured on its headquarters building in Mumbai April 1, 2013
A Novartis logo is pictured on its headquarters building in Mumbai April 1, 2013

A Novartis logo is pictured on its headquarters building in Mumbai April 1, 2013. REUTERS/Vivek Prakash

A Novartis logo is pictured on its headquarters building in Mumbai
A Novartis logo is pictured on its headquarters building in Mumbai

File picture shows a Novartis logo on its headquarters building in Mumbai April 1, 2013. Novartis raised its full-year outlook on July 17, 2013 after generic competition to its best-selling blood pressure pill was delayed, granting the Swiss drugmaker a temporary reprieve from patent losses. Picture

A logo is pictured on a building of Swiss drug maker Novartis before its annual general meeting in Pratteln
A logo is pictured on a building of Swiss drug maker Novartis before its annual general meeting in Pratteln

File picture shows a logo on a building of Swiss drug maker Novartis before its annual general meeting in Pratteln near Basel February 22, 2013. Novartis raised its full-year outlook on July 17, 2013 after generic competition to its best-selling blood pressure pill was delayed, granting the Swiss dr

File picture of a logo on a building of Swiss drug maker Novartis before its annual general meeting in Pratteln near Basel
File picture of a logo on a building of Swiss drug maker Novartis before its annual general meeting in Pratteln near Basel

File picture of a logo on a building of Swiss drug maker Novartis before its annual general meeting in Pratteln near Basel February 22, 2013. India's highest court has dismissed, April 1, 2013, Swiss drugmaker Novartis AG's petition seeking patent protection for its cancer drug Glivec, a serious blo